Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
MYMyriad Genetics, Inc. logo

Myriad Genetics, Inc. (MYGN)

NASDAQ · Currency in USD
$5.82 ▲ +0.06 (+1.04%)
At close: Oct 23, 4:00 PM ET. Market closed.
$5.82 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:54 PM ET

Summary

Previous Close
$5.76
Open
$5.72
Day's Range
$5.60 – $5.86
52 Week Range
$2.74 – $8.50
Volume
2,099,977
Avg. Volume
2,242,459
Market Cap
$556.68M
Beta (5Y Monthly)
1.64
PE Ratio (TTM)
--
EPS (TTM)
-$1.19
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
$21.00 (360.82%)
Ex-Dividend Date
Jul 1, 2009
1y Target Est
$4.82

Profile: Myriad Genetics, Inc.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
2,700
CEO
Samraat S. Raha
Website
myriad.com

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.17 · Revenue est. $191.33M
DateEst.Actual
Jul 30, 2026-$0.06-$0.25Miss
May 5, 2026-$0.06-$0.09Miss
Feb 23, 2026-$0.02$0.04Beat
Nov 3, 2025-$0.01-$0.13Miss
Aug 5, 2025-$0.01$0.05Beat
May 6, 2025-$0.05-$0.03Beat

Analyst view

Consensus price target
$4.82 ▼ -17.2%
Range $3.00 – $8.00
Rating: Hold
Buy 22% · Hold 59% · Sell 19%

Get free alerts on MYGN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.